SBI Securities’s Aptevo Therapeutics APVO Stock Holding History

SBI Securities’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$484	Hold	109	–	–	﹤0.01%	3042
2026 Q1	$465	Buy	109 +78	+252%	+$534	﹤0.01%	2916
2025 Q4	$292	Sell	31 -1	-3%	-$24	﹤0.01%	3080
2025 Q3	$827	Sell	32 -1	-3%	-$40	﹤0.01%	2772
2025 Q2	$1.79K	Buy	33 +31	+1,550%	+$5.65K	﹤0.01%	2433
2025 Q1	$813	Buy	+2	New	+$2.53K	﹤0.01%	2667
2024 Q4	–	Hold	0	–	–	–	2850

Other funds holding APVO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

SBI Securities's APVO Position: Q2 2026 in Review

SBI Securities held its Aptevo Therapeutics (APVO) position steady in Q2 2026 at 109 shares worth $484. The position accounts for ﹤0.01% of the portfolio, ranked #3042.

SBI Securities first reported a position in APVO in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.79K in Q2 2025. 2 funds tracked by Wall St. Rank hold APVO as of Q2 2026.

SBI Securities held 109 shares of Aptevo Therapeutics worth $484 as of Q2 2026.
SBI Securities left its Aptevo Therapeutics share count unchanged in Q2 2026.
Aptevo Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3042 holding.
SBI Securities first reported a position in Aptevo Therapeutics in Q1 2025 and has held it in 6 quarters since.
SBI Securities's Aptevo Therapeutics position peaked at $1.79K in Q2 2025.
2 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.